Biomarkers in Heart Disease. American Heart Association Clinical Series

  • ID: 2223991
  • Book
  • Region: United States
  • 256 Pages
  • John Wiley and Sons Ltd
1 of 4
Although the potential of biomarkers to enhance cardiovascular care is extremely bright, the challenge facing clinicians is determining how current and future biomarkers should be used in patient care, which is a fundamentally different process from early marker discovery.
Biomarkers in Heart Disease is the first title in the AHA Clinical Series and is aimed at meeting the needs of clinicians, providing cardiologists, internists, emergency physicians, laboratorians, and other healthcare providers with a clear understanding of the role of biomarkers in contemporary cardiovascular medicine.

The book covers both the strengths and pitfalls of currently available markers, and provides information on the most promising biomarkers that are likely to impact practice in the next few years. It is divided into four parts, organized around clinical scenarios rather than individual biomarkers:

biomarkers for the evaluation and management of patients with suspected acute and ischemic heart disease
heart failure diagnosis and monitoring
the increasingly important area of population screening
where the field is moving in the future.

This book will help the practicing physician decide which biomarkers to measure, when to measure them, how to interpret the results and how to make decisions based on the test result.
Note: Product cover images may vary from those shown
2 of 4
Part I Biomarkers for the Evaluation of Patients with Ischemic Heart Disease.

1 Protocols for Diagnosing Myocardial Infarction.

2 Troponin and Other Markers of Necrosis for Risk Stratification in Patients with Acute Coronary Syndromes.

3 Challenges Interpreting Cardiac Troponin Values.

4 Natriuretic Peptides and Inflammatory Markers for Risk Stratification in Patients with Ischemic Heart Disease.

5 Novel Markers in Patients with Suspected ACS.

Part II Biomarkers for Evaluation of Patients with Heart Failure.

6 Use of Natriuretic Peptides in the Diagnosis of Heart Failure.

7 Biomarkers for Risk Stratification in Patients with Heart Failure.

8 Natriuretic Peptides for Disease Monitoring in Patients with Chronic Heart Failure.

Part III Biomarkers for Screening in the Ambulatory Populations.

9 CRP.

10 Newer Markers for Population Screening.

Part IV A Look to the Future.

11 Moving Toward Personalized Medicine.

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
James de Lemos
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll